Vatorsecurities.se använder sig av cookies för att ge dig som besökare en så bra upplevelse som möjligt.

Analys

 

Vator Securities uppdragsanalys erbjuds till ett fåtal utvalda life science-bolag – ”By Invitation Only”.

 

Commissioned research: AlzeCure Pharma

24 oktober 2019

Biogen’s progress with its Alzheimer’s disease drug (aducanumab) gives support for the amyloid hypothesis and significantly strengthens AlzeCure’s case.

The company’s Alzstatin-program focuses on disease-modifying therapies for early Alzheimer’s disease by reducing the production of amyloid beta.

Commissioned Research: Bio-Works Technologies AB

19 september 2019

We believe that Bio-Works is now entering a new era as a professionally structured commercial player due to the following recent advancements;

i) consecutive quarterly customer growth; ii) fast traction in the important Protein A segment shortly post launch of the product WorkBeads affimAb; and iii) activist-like investments by the new owners and board members Peter Ehrenheim (Chairman) and Thomas Eklund (Director), holding a total of 17% together with a group of similar investors.

Commissioned Research: Immunovia AB

19 juni 2019

For the first time, test results with new blood, and across all risk groups Recent news flow from Immunovia has been intense and will continue to be intense in the coming quarters.

The news about the last phase of the IMMray PanCan-d optimisation was important for particularly two reasons, we believe.

Commissioned Research: Ascelia Pharma AB

18 juni 2019

Ascelia Pharma’s application to achieve patent coverage for a new Mangoral product has potentially several important implications, both in the medium and long term.

Following the planned 2022 launch of Mangoral in the US and Europe, the product’s orphan drug status and data exclusivity will protect sales for a period of between 7-10 years.

Commissioned research: Xbrane Biopharma AB

10 juni 2019

Xbrane Biopharma was founded in 2008 in Stockholm, Sweden, and is a late-stage drug development company focusing on biosimilars.

It became a publicly listed company in 2016 and in Q2 2018, the company entered into a strategic collaboration with Stada, Germany, covering the development and commersialisation of Xlucane, Xbrane’s biosimilar to the reference medicine Lucentis (ranibizumab).

Commissioned research: Immunovia AB

17 maj 2019

The news flow from Immunovia will be very intense and important in the coming months and quarters.

Regarding the company’s lead asset, IMMray PanCan-d, the last phase of the optimisation of the commercial signature and algorithm is ongoing, and results from the 1,600-sample test is planned to be reported by early June.

Commissioned research: AlzeCure Pharma

9 maj 2019

AlzeCure’s lead product asset, ACD855, started clinical development in late 2018 with the ambition to generate first clinical trials by early 2020.

However, early human exposure with the tablet product demonstrated that the concentration of the substance would require significantly longer dosing intervals than once daily, so the future development of the substance will now only be pursued with a formulation targeting ophthalmologic disorders.

Commissioned Research: Ascelia Pharma AB

25 april 2019

Ascelia Pharma is a Swedish based oncology company in late-stage development with a primary focus on contrast enhanced liver MRI for those with severely impaired kidney function.

The company’s management has extensive experience from rare diseases at large corporations, including Genzyme (acquired by Sanofi) and Wilson Therapeutics (acquired by Alexion).